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ALK  - Anaplastic lymphoma kinase 
ATRX  - Adenosine triphosphate dependent helicase ATRX  
CT  - Computed tomography 
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fl-TACR1 - Full length tachykinin receptor 1  
GPOH  - German society for pediatric oncology and hematology 
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IDRF  - Image defined risk factor 
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MYCN - V-Myc myelocytomatosis viral related oncogene, neuroblastoma                 
 derived, homolog 
MYCNOS - V-Myc myelocytomatosis viral related oncogene, neuroblastoma             
 derived, homolog, opposite strand 
NB    - Neuroblastoma 
NK1R  - Neurokinin 1 receptor  
NK1R-F  - Neurokinin 1 receptor, full length 
NK1R-T  - Neurokinin 1 receptor, truncated 
NRAS  - Neuroblastoma rat sarcoma proto oncogene 
NSE  - Neuron specific enolase 
OS  - Overall survival 
PCR  - Polymerase chain reaction 
PHOX2B  - Paired like homeobox 2B 
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TACR1  - Tachykinin receptor 1 
TBP  - TATA box binding protein 
TRKA  - Tropomyosin receptor kinase A 
tr-TACR1 - Truncated tachykinin receptor 1 
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Neuroblastoma (NB) is the most common, extracranial solid tumor amongst children [1, 2]. 
Next to hepatoblastoma, nephroblastoma and the group of primitive neuroectodermal 
tumors, it belongs to the category of embryonal tumors. It has a yearly incidence of 
approximately 1.3 / 100.000 children in Germany, which means about 140 newly diagnosed 
cases of NB per year. NB represents about 8-10% of all pediatric malignancies, in which a 
slight surplus of male patients can be found (male: female = 1.3:1.0) [1, 3]. 
The median age of all patients at time of diagnosis is about 17 months. Among all diagnosed 
children, 90% are younger than six years, and 40% have not even finished their first year of 
life [2, 4]. Less than 3% of all NBs are newly diagnosed during adolescence [5, 6].  
Originating from mis-differentiated multipotent cells of the neural crest, NB arises from the 
sympathetic autonomic nervous system [7]. According to this, NB is often associated with 
other diseases, which have their origin in a failed development of neural cells – for example 
Turner syndrome, Hirschsprung’s disease, Ondines disease, Noonan-Costello - syndrome or 
Neurofibromatosis Recklinghausen [8-11]. Besides the correlation with syndromic diseases, 
there is also a rare proportion of familial accumulation in NB [12]. 
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NB is characterized by its very variable course of disease, including autonomous complete 
regression as well as therapy-resistant disease progress. Responsible factors for this 
phenomenon are not exactly known by now, although research has helped a lot to get new 
insights in molecular functions in NB and improved therapy within the last 30 years. Thus, 
the 5-year overall survival (OS) was increased from 52% up to over 74% [2]. However, 
despite tremendous progress in diagnostic and therapeutic measures, NB still causes about 
15% of all fatalities in pediatric oncology [13].  
 
2.1.2 Clinical and diagnostic examinations 
Whereas in many cases NB is accidentally recognized during a routine sonography, its 
displacing growth can also lead to symptomatic suffering [14].  
NB can most frequently be found in the tissues of the adrenal medulla and the paravertebral 
sympathetic trunk. In the majority of cases, the tumor is located in the abdominal space, 
followed by localizations in cervical or thoracic area, as well as in the pelvis [7, 15-17].  
Metastasis occurs in skeleton, bone marrow, lymph nodes, liver and skin. An infestation of 
the central nervous system or the lung is rarely seen [18]. Depending on the location, 
excessive tumor growth can generate urinary retention, dyspnea or an affection of nervous 
tissue. This can result in varying neurological deficits like Horner syndrome or 
Opsomyoclonus syndrome [19]. Furthermore, overexpression of catecholamines can cause 
high blood pressure, diarrhea or hot flashes [1, 8, 15, 20]. 
Furthermore, frequently unspecific, general symptoms as fatigue, anorexia, diffuse pain or 
dystrophia can be found. A rare, but mostly misinterpreted sign are the so called “raccoon 
eyes”, a periorbital ecchymosis caused by a tumor infiltrating palpebral vessels [21].  
Even though several studies reported about a screening method for detection of NB with 
urine catecholamines more than twenty years ago, there was unfortunately no therapeutic 
benefit.  
While the frequency of diagnosed NB increased rapidly, mortality remained unaffected. This 
was explained by diagnosis of tumors, which would have never been clinical apparent 
without the urine analysis because of their spontaneous remission. Analysis of the studies 
showed once again the problem of the variable course of disease; thus, the screening was 
omitted to avoid overdiagnosis and –treatment [22-24]. 
However, the surplus of catecholamines and their degradation products in urine or serum 
can be used for diagnostic measuring.  
For a full diagnostic work-up, neuron-specific enolasis (NSE), lactate dehydrogenase (LDH) 
and ferritin should be analyzed by blood samples as well. Additionally, imaging like 
sonography, MRI, CT-scan and I123 -metaiodobenzylguanidine (mIBG) - or skeleton-
scintigraphy are implemented to visualize the extent of growth and affection of nearby 
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organs or tissues. As over 50 percent of NB patients show bone marrow infestation, a biopsy 
is recommended [25]. A biopsy of the tumor itself is necessary for histopathological analysis 
and identification of genetic alterations to provide an efficient staging [18]. 
 
2.1.3 Genetics 
Despite intensive research, a single initiating factor for formation of NB is still not known up 
to now  [26]. So far, many different gene alterations and –products seem to participate in 
the origin of NB. A complex interplay of promotion and inhibition of inter- and intracellular 
signaling pathways influences the biology of the tumor and is still not fully understood [4].  
However, recent studies give insights in genetic characteristics of NB. So, the sporadically 
overexpressed ALK gene in combination with the PHOX2B gene was identified as a 
characteristic initiator for the hereditary form of NB, representing about 1% of all NB cases 
[27, 28].  
Further alterations in genes like ATRX, NRAS, and TRKA are objects of current research as 
well as losses and gains of the chromosomes 1p and 17q, respectively [29-34]. Recent 
studies have also described a major role of telomerase activation and telomere maintenance 
in the progression of especially high-risk NB [35, 36]. 
But despite all these new insights, amplification of the MYCN - oncogene is still the most 
relevant factor for a reliable staging and prognosis of NB [37-39]. Amplification of MYCN 
starting from a tripling of the gene up to several thousand copies is detected in about 19% to 
30 % of NB, depending on the investigated patient group [38, 40, 41]. 
MYCN functions as a tissue specific proto-oncogene, which is regularly present during the 
embryonal period. [37, 41-43]. Regulating the cell cycle, it is able to influence proliferation 
and cellular transformation as well as apoptosis and cellular transcription. It also plays a 
major role in metastasis of tumors with an amplification and overexpression of the gene [44-
47]. As MYCN is also recognized to have an impact on cell adhesion, motility, migration and 
angiogenesis, it is known to affect the course of disease in a prognostically unfavorable way 
[48-52]. 
While MYCN is known as one of the most powerful genetic factor in staging and prognosis of 
NB, in latest studies MYCNOS or also called N-CYM, an antisense transcript of MYCN, 
containing 109 amino acids and also located on chromosome 2p23-24 , was found to be a 
relevant co-factor in angiogenesis, vascularization and tumorous vessel affection [13, 38, 53-
60]. Due to its obligatory co-expression and its stabilizing effect on MYCN, it is subject to a 
mechanism of positive auto-regulation, triggering cells‘ survival and increasing potential for 
aggressive growth as well as risk for metastatic spreading by inhibiting apoptosis in case of 




2.1.4 Histological grading and staging 
Histopathological analysis is obligatory for exact diagnosis and treatment of NB. Microscopic 
examination of tumor sections generally shows accumulations of small, immature basophil 
cells. Furthermore, granules containing catecholamines and chromogranine A as well as 
expression of neurofilaments and S100 protein are seen. Depending on grade and quantity 
of differentiated cells in tumor tissue, NB can be defined into three different grades by the 
Hughes index [64, 65].  
Histological grading is used in connotation with mitosis-karyorrhexis-index and individual 
factors such as age at diagnosis for the international NB pathology classification (INPC). This 
was developed from the Shimada classification trying to derive a prognosis from 
histopathological results [66].  
Furthermore, there are two established clinical staging systems for NB.  
The international NB staging system (INSS) regards localization and extent of tumor growth 
in reference to the midline, metastasis, affection of lymphatic nodes and age to divide 
patients in five different subgroups. Unfortunately, it also refers to extent of resection and 
so it is not able to provide a pre-surgical risk stratification [67].  
The international NB risk group stratification system (INRGSS) is based on several criteria 
such as age, gene alterations, imaging and histological category of the tumor [68]. Here, 
image defined risk factors (IDRF) helping to evaluate an affection of nearby organs by the 
tumor in the diagnostic imaging are particularly noteworthy. In opposite to the INSS, the 
INRGSS is independent from individual surgical skills and has the advantage of a pre-
therapeutic risk assessment [69]. 
According to these risk stratification models patients can be allotted to different risk groups, 
in which an age older than 18 months, metastasis and especially an amplification of MYCN  
are considered as prognostically poor criteria [68].  
 
2.1.5 Treatment and prognosis 
In their current treatment protocol (NB 2004) the German Society for pediatric oncology and 
hematology (GPOH) uses a risk stratification system categorizing patients into three risk 
groups (low, intermediate and high risk). This results in 3 different therapeutic approaches 
[70].  
A regular observation or primary surgical resection is recommended for patients with low 
risk, while patients of the intermediate risk group should receive neo-adjuvant 
chemotherapy consisting of alternating cycles of cisplatin, etoposide, vindesine, vincristine, 
dacarbacin, doxorubicin, ifosfamid and cyclophosphamide, followed by surgical resection, 
adjuvant chemotherapy and possibly radiotherapy [71]. 
11 
 
The therapeutic concept for the high risk group contains intensified neo-adjuvant 
chemotherapy with a gross-total resection and a following high-dose consolidation therapy 
with autologous bone marrow transplant as well as a post-consolidation therapy. 
Furthermore, in case of mIBG-positive tumors, a therapy with I123-mIBG can be taken into 
consideration [71, 72]. 
Outcome of patients with NB is quite variable, depending on multiple factors such as age at 
diagnosis, grade of differentiation, genetic alterations, resectability and comorbidities.  
It reaches from 30% with stage 4 patients up to over 95% with low risk patients in 
observation groups [68, 73, 74].  
Although 5-year OS rates increased from 52% to over 75% during the last decades, this 
improvement refers primary to advanced therapy for patients at lower stages, while high risk 
patients still are a challenge to treat [2]. Over 50% of all high risk patients show relapse and 
also second malignancies during their lifetime [2, 75, 76]. 
 
 
2.2 Aims of the studies 
The present thesis includes two studies focusing on NB.   
In the first study, we analyzed a special growth form of vessel adherent NB and its clinical 
relevance for surgical resection and the further course of disease. Furthermore, we 
investigated the role of MYCN expression levels to serve as a potential biomarker for vessel 
infiltrative growth. 
In a second study, we investigated the role of the neurokinin-1 receptor as a possible target 
for therapeutic interventions in NB.  
In the following, the concept and realization of each study is shortly explained. 
 
2.2.1 Vessel adherent growth represents a major challenge in the surgical resection of 
neuroblastoma and is associated with adverse outcome 
Despite all diagnostic and preoperative examinations, many cases of NB treated at the 
department of pediatric surgery of the Ludwig-Maximilians-University Munich show 
intraoperatively an unexpected vessel adherence impeding a complete resection.  
While some tumors can easily be separated from nearby vascular structures without any 
damage of the vascular tissue, others show infiltrative growth into adjacent vessels. Due to 
this infiltrative adherence, this growth behavior seems to increase the risk for vascular 




Although IDRFs define the proximity of the tumor to larger vessels in diagnostic and 
preoperative imaging, they are not able to specify the affection of vessels in a macroscopic 
and microscopic way before surgical intervention [69, 77]. Earlier research only focused on 
the extent of vessels’ encasement by the tumor and its impact on the course of disease [77]. 
So up to now, there is no current study differentiating between varying forms of vessel 
affection or describing the observed vessel infiltrative growth of NB. 
The purpose of our study was to describe and quantify the phenomenon of vessel infiltrative 
growth by NB and to investigate its impact on the course of disease. 
As none of the current imaging studies are able to detect this vessel affection, gene 
expression levels of MYCN and MYCNOS were measured in tumor samples in an attempt to 
find predictive molecular markers for this phenomenon. 
The examined cohort contained 100 patients with NB, who received surgical treatment in 
our department. Diagnostic, staging and therapy was performed according to international 
standards.  
Retrospective data analysis included 15 clinical parameters such as histopathological 
analysis, genetic alterations, course of disease and surgical characteristics such as 
localization of the tumor, extent of resection and adherence to nearby structures. Here, the 
sort of vessel affection was especially considered. 
Gene expression levels of MYCN and MYCNOS were determined in RNA extracted from 
homogenized tumor tissue of every single patient.  
Candidate gene expression analysis was performed by real-time PCR and set in ratio with 
TBP (TATA-box binding protein) as a housekeeping gene. Expression values were correlated 
with the clinical parameters and grade of vessel affection.  
Comparison of infiltrative and non-infiltrative tumors according radiologic imaging showed 
no possibility to differentiate between these growth behaviors only by regarding IDRF- or 
encasement status.  
We were the first to define the phenomenon of unexpected vessel infiltration of NB (UVIN) 
and histopathologically proved that the tumor cells only reached into the superficial vascular 
wall layers without penetrating the lumen. Statistical analysis showed an appearance of 
UVIN in over one third of all patients as well as significant correlation of infiltrative growth 
with occurrence of complications, extent of resection, neoadjuvant chemotherapy, MYCN-
amplification, IDRF positivity and vessel encasement. 
Analyzing gene expression levels, our results showed that neither MYCN nor MYCNOS were 
appropriate markers for infiltrative growth of NB, even though the important role of MYCN 




This study described for the first time the phenomenon of UVIN and demonstrated its 
relevance for the course of disease. 
Considering the fact that there is no current method to detect UVIN by internistic or 
radiologic diagnostic, it also showed the need for an improved pre-surgical risk assessment.  
Furthermore, prospective studies on larger cohorts should be used to identify marker genes 
and to provide deeper insights into biological and molecular functions of vessel adherent NB.  
 
2.2.2 Expression of Truncated Neurokinin-1 Receptor in childhood neuroblastoma is 
independent of tumor biology and stage 
Treatment of NB is still a therapeutic challenge because of its variable course of disease. 
Current research aims for the identification of prognostic and predictive molecular markers 
to provide a better understanding of biological mechanisms in NB, leading ultimately to an 
establishment of targeted therapies. 
Recent results on other embryonal tumor entities, especially on pediatric hepatoblastoma, 
demonstrated neurokinin-1 receptor – also known as substance P-tachykinin receptor 
(TACR1) – as a potential target for supportive therapy [78-80]. Here, growth of 
hepatoblastoma cells could effectively be reduced by neurokinin receptor antagonists in 
vitro and in vivo [81]. 
The neurokinin-1 receptor occurs in two naturally existing isomers, a full-length splice 
variant (fl-TACR1 or NK1R-F) and a truncated splice variant (tr-TACR1 or NK1R-T). Containing 
a hundred amino acids less on its C-terminal end than the full-length variant, it differs in its 
interaction with substance P [82-84].  
The activated form of tr-TACR1 lacks a negative feedback function, resulting in a continuous 
activation. Furthermore, its activated complex can also be responsible for angiogenesis in 
tumors and inflammatory processes [83, 85].  
Latest research on targeted therapy in hepatoblastoma investigated the influence of 
neurokinin-1 receptor antagonists on these cellular mechanisms. 
Treatment of in vitro and in vivo cell line models with aprepitant, a common NK1R – 
antagonist originally used for chemotherapy-induced nausea and vomiting, resulted in 
reduced tumor growth, decreased angiogenesis and a higher rate of apoptosis [86]. 
The purpose of this study was to investigate if the aforementioned insights in 
hepatoblastoma can be transferred to the therapy of NB.  
The study cohort included 59 NB patients – treated according to the NB 2004 protocol of the 
German Society of Pediatric Oncology and Hematology – who underwent resection of NB in 
our department.  
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Clinical parameters such as age, gender, outcome, metastasis, INSS status, MYCN status, 
histology, and extent of surgical resection were analyzed retrospectively and correlated to 
gene- expression levels of fl-TACR1 and tr-TACR1.  
For that reason, RNA was extracted from every single tumor sample and gene expression 
levels were measured by real-time PCR in ratio to TBP (TATA-box binding protein) as a 
housekeeping gene.  
Our study showed significantly increased gene-expression levels of tr-TACR1 in examined NB 
samples. Statistical analysis revealed only fl-TACR1 to be associated with INSS grade 4.  
Correlation analysis of the other clinical parameters showed significant results neither with 
tr-TACR1 nor with fl-TACR1. 
Our study demonstrated ubiquitously increased expression of tr-TACR1 in NB, independent 
of biological or individual factors. However, these results should be verified by further 
studies in larger cohorts. 
Collectively, our study underscores the significance of TACR1 as a promising target for 




The postgraduate Jakob Mühling contributed to both publications by selection of patients 
and collection of patients’ data. He processed frozen tumor tissues by slicing and HE-staining 
all samples for histopathological analysis.  
Additionally, he extracted RNA from tumor tissue and performed real-time PCR analysis for 
investigation of gene-expression levels of MYCN and MYCNOS.  
In the first publication „Vessel adherent growth represents a major challenge in surgical 
resection of neuroblastoma and is associated with adverse outcome“ he was responsible for 
data evaluation and statistical analysis. Furthermore, he drafted the manuscript and 
designed graphics. 
Aforementioned patients‘ data and statistical analysis were also used for the second 
publication „Expression of Truncated Neurokinin-1 Receptor in childhood neuroblastoma is 
independent of tumor biology and stage“, where Jakob Mühling was involved in data analysis 








3.1 Summary in English 
Neuroblastoma (NB), an embryonal malignancy arising from the sympathetic nervous 
system, is known as the most common solid extracranial tumor amongst pediatric patients. 
It usually affects children under the age of six years with an incidence of about 140 newly 
diagnosed cases per year in Germany. Because of its highly inconstant course of disease, 
including spontaneous regression as well as progressive tumor growth with metastasis, 
therapeutic approaches reach from controlled observation to surgical intervention as well as 
high-dose chemotherapy with stem cell transplant and irradiation, with varying outcome.  
Except for the amplification of the MYCN proto-oncogene and deletion of chromosome 1p, 
no strong predictors of outcome have been described so far. 
Our research reported in the two publications was directed towards i) describing a new 
phenomenon that occurs intraoperatively during tumor resection and might influence the 
course of disease and ii) characterizing a new molecular target that might be used for future 
therapeutic interventions. 
The first study “Vessel adherent growth represents a major challenge in the surgical 
resection of neuroblastoma and is associated with adverse outcome“ describes a specific 
growth behavior of NB that we termed ”unexpected vessel infiltration of NB (UVIN)”. During 
operation, thus unexpectedly, these tumors present with a strong adherence to vessels that 
impedes complete resection without relevant damage of the affected vessels, as opposed to 
another type of tumors with macroscopic identical structures also surrounding, but not 
infiltrating nearby vessels and that are easily resectable. 
Histochemistry identified that cells of UVIN tumors only infiltrate the outer vessel layers 
without penetrating into the lumen.  
Data analysis of 100 patients treated at the Department of Pediatric Surgery of the Ludwig-
Maximilians-University in Munich revealed that UVIN is detectable in over a third of all NB 
patients. This special growth behavior could not be identified by pre-operative diagnostic 
imaging and was significantly correlated with a worse course of disease. Statistical analysis 
showed that expression levels of the genes MYCN and MYCNOS are no appropriate markers 
to identify UVIN. 
Our second study “Expression of Truncated Neurokinin-1 Receptor in childhood 
neuroblastoma is independent of tumor biology and stage“ focused on possible approaches 
for targeted therapy in NB.  
We investigated the role of the neurokinin-1 receptor, known as a potential target structure 
in the treatment of hepatoblastoma, in a cohort of 59 NB patients. 
We showed similar expression levels of the truncated neurokinin-1 receptor, a splice variant 
that differs from the full-length transcript in its constant activation, in all examined samples 
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of NB. Accordingly, by correlating expression data with several clinical characteristics, no 
significant correlation with tumor biology and stage of the tumor was found. These data 
clearly define neurokinin-1 receptor as a generally overexpressed gene in NB independent of 
other biological or clinical factors, thereby advocating it as a promising target for further 
therapeutic approaches in NB patients. 
Collectively, we were the first to define a special growth behavior of NB termed UVIN and its 
clinical relevance, and additionally identify NK1R as a target to potentially improve a 
successful therapy of this extraordinary tumor in the future. 
 
 
3.2 Summary in German 
Das Neuroblastom ist als embryonaler Tumor des sympathischen Nervensystems der am 
häufigsten extrakraniell auftretende solide Tumor des Kindesalters. Überwiegend sind Kinder 
bis zum sechsten Lebensjahr betroffen, wobei die Inzidenz in Deutschland bei etwa 140 neu 
diagnostizierten Fällen pro Jahr liegt. Die Therapieansätze zur Behandlung des 
Neuroblastoms sind ebenso variabel wie sein Verlauf, der von spontaner Regression bis hin 
zu fortschreitendem Tumorwachstum mit Metastasierung reicht. Abhängig vom 
Krankheitsstadium werden Patienten entweder lediglich beobachtet oder einer Operation 
zugeführt, die teilweise noch um mehrere Zyklen einer Hochdosis-Chemotherapie, eine 
Stammzelltransplantation oder eine Strahlentherapie ergänzt werden muss. Die 
Überlebensraten sind hierbei – je nach Zugehörigkeit der Patienten zu verschiedenen 
Risikogruppen – sehr unterschiedlich. 
Als stärkste prognostische Faktoren sind bisher die Amplifikation des MYCN Proto-Onkogens, 
sowie eine Deletion auf dem 1p-Chromosom bekannt. 
Unsere Forschungsarbeit, aus der die beiden vorliegenden Publikationen hervorgegangen 
sind, war zum einen darauf ausgerichtet, ein neues Wachstumsphänomen des 
Neuroblastoms, welches intraoperativ während der Resektion auffällig wird, und dessen 
möglichen Einfluss auf den Krankheitsverlauf zu untersuchen, zum anderen analysierten wir 
Neuroblastomproben hinsichtlich eines Zielmoleküls, das potentiell für zukünftige 
Therapieansätze genutzt werden könnte. 
Die erste Studie mit dem Titel “Vessel adherent growth represents a major challenge in the 
surgical resection of neuroblastoma and is associated with adverse outcome“ beschreibt 
eine spezifische Wachstumsform des Neuroblastoms, welche wir als ”unexpected vessel 
infiltration of neuroblastoma (UVIN)” betitelten. Die entsprechenden Tumoren fallen hierbei 
intraoperativ unerwarteter Weise durch eine starke Verwachsung mit den umliegenden 
Gefäßen auf. Dies verhindert eine komplette Resektion des Tumors ohne einen relevanten 
Schaden des betroffenen Gefäßes zu provozieren. Im Gegensatz hierzu sind andere, 
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makroskopisch identisch erscheinende und die Gefäße ebenfalls umschließende, aber nicht 
infiltrierende Tumoren leicht zu resezieren. 
Histopathologisch zeigte sich, dass die Zellen von UVIN-positiven Tumoren lediglich in die 
äußeren Schichten der Gefäßwände einwachsen ohne in das Gefäßlumen vorzudringen. 
Die Analyse der von 100 Patienten, die alle in der kinderchirurgischen Klinik der Ludwig-
Maximilians-Universität München behandelt wurden, erhobenen Daten zeigte, dass UVIN in 
über einem Drittel aller Neuroblastom-Patienten auftritt. Diese spezielle Wachstumsform 
konnte nicht durch die präoperative diagnostische Bildgebung dargestellt werden und war 
signifikant mit einem schlechteren Krankheitsverlauf assoziiert. Die statistische Analyse 
ergab, dass die Expressionslevel der Gene MYCN und MYCNOS nicht als geeignete Biomarker 
zur Identifikation von UVIN genutzt werden können. 
Unsere zweite Studie mit dem Titel “Expression of Truncated Neurokinin-1 Receptor in 
childhood neuroblastoma is independent of tumor biology and stage“ verfolgte den Ansatz, 
neue Möglichkeiten zur gezielten Therapie beim Neuroblastom aufzuzeigen. 
Wir untersuchten hierzu an einem Kollektiv von 59 Neuroblastom-Patienten die Rolle des 
Neurokinin-1 Rezeptors, der bereits bei der Therapie des Hepatoblastoms als mögliche 
Zielstruktur bekannt geworden ist. 
Die Analyse ergab in allen untersuchten Neuroblastomproben ähnlich hohe Expressionen 
des verkürzten Neurokinin-1 Rezeptors tr-TACR1. Diese Spleißvariante des Neurokinin-1 
Rezeptors unterscheidet sich von der ungekürzten Form fl-TACR1 durch seine kontinuierliche 
Aktivierung.  
Gemäß den ubiquitären Expressionsraten zeigte sich bei deren Korrelation mit mehreren 
klinischen Kriterien kein signifikanter Zusammenhang mit der Tumorbiologie oder dem 
Tumorstadium. 
Aufgrund der Tatsache, dass der Neurokinin-1 Rezeptor bei Neuroblastom-Patienten 
unabhängig vom Krankheitsverlauf oder biologischen Faktoren generell überexprimiert wird, 
ist er als vielversprechendes Zielmolekül für zukünftige Therapieansätze prädestiniert.  
Zusammengefasst konnten wir durch unsere Studien erstmalig eine spezielle 
Wachstumsform des Neuroblastoms - genannt UVIN – und seine klinische Relevanz 
beschreiben und zusätzlich den Neurokinin-1 Rezeptor als mögliches  Zielmolekül für eine 
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Purpose: Neuroblastoma (NB) is the most common extracranial, solid tumor in childhood, with a peak incidence
in children under 6 years of age. Due to its variable course of disease, which ranges from spontaneous regression
to metastatic spread, NB still represents a significant therapeutic challenge. Strikingly, a certain number of NBs
intraoperatively show vessel adhesion and/or infiltrative growth, which is often not visible in pre-operative im-
aging.We proposed the term unexpected vessel infiltration of NB (UVIN) to denote this phenomenon. UVIN rep-
resents a major surgical challenge.
Methods: In this study, we determined frequency and clinical relevance of UVIN in a cohort of 100 NB-patients
with subsequent correlation to several unfavorable characteristics of disease. RNA expression levels of MYCN
and its co-regulated antisense transcript MYCNOS to identify markers was measured by PCR.
Results: We found UVIN to be present in 34% of cases and significantly correlated with incomplete resection,
MYCN amplification, complications, neoadjuvant therapy, tumor grade and MYCNOS expression levels. MYCN
expression levels showed no significant results with UVIN.
Conclusion: Collectively, our data show that UVIN represents a frequent surgical problem associated with a poor
outcome in NB patients. MYCN and MYCNOS seem to be no appropriate markers for UVIN.
Type of study: Prognosis study.
Level of evidence: Level III.
© 2019 Elsevier Inc. All rights reserved.
NB is themost frequent, extracranial solid malignancy in the pediat-
ric population. It arises from the autonomic, sympathetic nervous sys-
tem and originates from misdifferentiated progenitor cells of the
neural crest. Hence, this tumor most frequently presents in the abdom-
inal cavity, followed by the cervical, thoracic and pelvic areas [1,2]. De-
spite the tremendous advances in the diagnostic and therapeutic
management options available for NB over the last 30 years, this
tumor is still responsible for about 15% of all oncologic pediatric mortal-
ities [3]. NB shows an extremely variable disease course, with some
patients demonstrating spontaneous remission, whereas others prog-
ress and die due to the disease. Fifty percent of all NBs have alreadyme-
tastasized at the time of diagnosis [4].
In spite of intensive research, no clear driver for the formation of NB
has been identified so far. A complex interplay ofmany different genetic
alterations, such asMYCN amplification, ALK activations and TERT rear-
rangements, seem to influence the biology of this tumor [5–7]. Of
these, amplification of MYCN appears to be the most important factor
for staging and prognosis in NB [3,8]. MYCN is a proto-oncogene that
is physiologically present in early stages of embryonic development
and influences the regulation of cell cycle, proliferation, apoptosis and
cellular transcription [9]. The frequency of MYCN amplification in NB is
estimated to be 20%, with amplification being defined as at least three
copies of the gene [1,10]. PatientswithMYCN amplification demonstrate
a significant decrease in survival [3,8,11].
The so-called N-CYM or MYCNOS gene, found at the chromosomal
locus 2p23–24, on the opposite DNA strand to MYCN, is also thought
to be involved in NB. This gene is transcribed in antisense to MYCN.
MYCNOS promotes the expression of MYCN by interfering with other
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factors and thus stabilizing the MYCN products [12,13]. In view of its
obligatory co-expression with MYCN, a positive auto-regulation has
been anticipated [14,15]. Concomitant overexpression of MYCN and
MYCNOS increases not only cell survival and aggressive growth but
also the risk for metastasis due to inhibition of apoptosis [12,16].
Owing to its molecular genetic variety, NB represents an extraordi-
nary therapeutic challenge, with surgical intervention playing a major
role [17,18]. Close contact of the tumorwith vital structures, particularly
blood vessels, can be a significant problem during attempts at surgical
resection and can potentially result in incomplete resections. Important
blood vessels have often been found to be affected in locally advanced or
metastatic NB and the impact this has on the clinical course of the dis-
ease has been well documented [19]. As a consequence of these issues,
assessment of image-defined risk factors (IDRF) is one of the first diag-
nostic steps inNB evaluation including the assessment of vessel involve-
ment. This information then influences the preoperative INRGSS staging
of theNB. Despite this however, surgical complications are still regularly
encountered. This is because of the presence of strong adhesion of some
of the tumors to the vessel walls, a phenomenon which is independent
from the extent of encasement of thosewalls as determined by the pre-
operative imaging. [20].
The aim of this study was to document this invasive growth phe-
nomenon in a systematic way and investigate its clinical relevance for
the course of disease. Furthermore, we evaluated the expression of
MYCN and MYCNOS as putative molecular indicators for this invasive
growth pattern of NB.
1. Material and methods
1.1. Patients
One hundred patients of Caucasian origin with NB were treated be-
tween 2009 and 2016 in the department for pediatric surgery at the Dr.
von Hauner children's hospital, Munich, Germany. All tumors were
resected or assisted and documented for the occurrence of vessel adhe-
sive growth by the same surgeon (D.v.S.). Diagnosis, therapy and stag-
ing were performed according to current guidelines and international
standards (grading: INRG; staging: INSS). Patients were treated accord-
ing to the standard protocol (NB 2004, German Society of Pediatric On-
cology and Hematology, GPOH). Written informed consent was
obtained from the patients' parents or the patient itself and the study
protocol was approved by the Committee of Ethics (Ludwig-
Maximilians-University of Munich).
Patients' charts were reviewed retrospectively for age, sex, INSS
stage,MYCN amplification, metastasis, extent of resection, histology,
complications, recurrence, neoadjuvant therapy, event-free survival
(EFS) and outcome (overall survival, OS). INSS stages 1, 2 and 4S
were defined as low grade, 3 and 4 as high grade disease. Death or re-
currence was defined as events in EFS. (see Table 1, column 1 & 2).
Tumor tissue from each patient was frozen in liquid nitrogen for fur-
ther analysis.
1.2. Categorizing the type of vessel involvement
Three categories of vessel involvement were defined. Firstly, preop-
erative imaging studies at the time of diagnosis were reviewed for the
occurrence of IDRF (concerning vessel encasement) as described by
Monclair et al. [21]. The tumors were thus identified as IDRF-positive
or IDRF-negative.
Secondly, tumorswere differentiated based on the degree of “in situ”
vessel involvement asNB frequently presents intraoperatively as amass
closely associated with bigger vessels, such as the caval or renal vein.
Envelopments of more than 50% of a vessel in situ were classified as en-
casement of the affected vessel. The tumors were thus identified as
“encasing” or “not encasing” [19].
Thirdly, in the category of encasing tumors, we differentiated tu-
mors into two subsets. The first of these had macroscopically visible
vessel infiltration and were difficult to remove from the affected ves-
sels. The second of these could be quite easily separated from the
vessel surface without causing any damage. To denote this phenom-
enon, we propose the term “unexpected vessel infiltration of
Table 1
Clinical characteristics and correlation with UVIN. Apart from different kinds of vessel
involvement, 13 additional parameters were analyzed in 100 patients. Grade 1, 2A, 2B
and 4S are classified as low grade, 3 and 4 as high grade (columns 1&2). The analysis for
correlation of UVIN and all clinical characteristics was performed with GraphPad Prism
in Chi-Square tests at a p-value lower than 0.05. Frequency is given in number of patients
and percentage inparentheses. Significant results (bold printed)were found in correlation
with complications, MYCN-amplification, extent of resection, IDRF vessel status, encase-












Recurrence p = 0.4545
Yes 22 9 (40.9) 13 (59.1)
No 78 25 (32.1) 53 (67.9)
Complications p = 0.0344
Yes 49 22 (44.9) 27 (55.1)
No 51 12 (23.5) 39 (76.5)
Metastasis p = 0.0588
Yes 48 21 (43.8) 27 (56.2)




Yes 13 9 (69.2) 4 (30.8)
No 87 25 (28.7) 62 (71.3)
Sex p = 0.2951
Male 52 15 (28.8) 37 (71.2)




Incomplete 63 28 (44.4) 35 (55.6)




Yes 81 34 (42,0) 47 (58.0)




Positive 60 30 (50.0) 30 (50.0)
Negative 40 4 (10.0) 36 (90.0)
Encasement p b 0.0001
Positive 64 34 (53.1) 30 (46.9)






62 22 (35.5) 40 (64.5)
b 18
months
38 12 (31.6) 26 (68.4)
Outcome p = 0.0683
Dead 21 11 (52.4) 10 (47.6)




With event 32 15 (44.4) 17 (55.6)
Event free 68 19 (16.2) 49 (83.8)
Grade p = 0.0014
High grade 80 33 (41.3) 47 (58.7)




Thoracic 8 2 (25,0) 6 (75,0)
Abdominal 92 32 (34,8) 60 (65,2)
Histology p = 0.9406
GN 8 3 (37,5) 5 (62,5)
GNB 34 11 (32,4) 23 (67,6)
Diff. NB 29 11 (37,9) 18 (62,1)
Undiff. NB 29 9 (31,0) 20 (69,0)
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neuroblastoma” (UVIN). The encasing tumors were therefore either
UVIN positive or UVIN negative.
1.3. Histopathological analysis
Histological examination of each tumor was performed on
hematoxylin–eosin stained sections of formalin-fixed paraffin-
embedded tissues by a trained pathologist (J.M.-H.). Immunohisto-
chemical staining of neuron-specific enolase (NSE) was performed on
formalin-fixed paraffin-embedded tissue sections using a pretreatment
of 15′min in citrate buffer in the microwave, followed by an incubation
with an antibody against NSE (DakoCytomation, Hamburg, Germany;
1:50) and alkaline phosphatase anti-alkaline phosphatase detection as
previously described [22]. Special microscopic imaging was done in
one of three most representative tumors, which unfortunately led to
the resection of affected organs as kidney and adrenal gland.
1.4. RNA isolation and cDNA synthesis
RNA was isolated from fresh frozen tumor tissue of every single pa-
tient using TRI reagent (Sigma Aldrich International, St. Gallen,
Switzerland) according to the manufacturer. cDNA was synthesized
from 2 μg RNA using random hexameres (Roche Diagnostics,
Mannheim, Germany) and SuperScript II (Invitrogen) as recommended
by the supplier.
1.5. Real-time PCR
We quantified gene-expression levels of MYCN, MYCNOS and TBP
(TATA box binding protein) using TaqMan assays (HS 00232074 m1,
HS01040745m1, HS00427620m1 from Life Technologies, Carlsbad, CA,
USA). PCR reactionswere set upwith TaqManMasterMix (Life Technol-
ogies) and run in duplicates on a Mastercycler Realplex2 cycler
(Eppendorf, Hamburg, Germany).
Amplification of the housekeeping gene TATA-Box-binding-Protein
(TBP) was performed to standardize the amount of sample RNA. Rela-
tive quantification of gene expression was performed using the ΔΔct
method as previously described [23].
1.6. Statistical analysis
Non-parametric Spearman correlation and association studies of ex-
pression data with clinical parameters using the Fisher's exact test were
performed in GraphPad Prism. Estimates for survival were generated
using the Kaplan–Meier method, and curves were compared by using
log-rank test. A level of p b 0.05 was considered to be significant.
Fig. 1. Different forms of vessel involvement and their appearance “in situ” and in diagnostic imaging. Intraoperative pictures above show tumors with encasement (left) and
infiltrative growth (right). While tumor tissue (marked with stars) could be easily separated from the encased vessel (left side: renal veins and caval vein), the resection of the
infiltrative tumor endangered the integrity of the affected vessel (right side: inferior mesenteric artery, marked with A, U shows the ureter). As visible on CT scans of the same patients
(below), the quality of vessel contact in affected areas is not predictable. Both were defined as “IDRF vessel” positive. For better orientation, organs are marked with L = liver and K =
kidney.
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2. Results
2.1. IDRF-positive tumors and encasement
First, diagnostic imaging was reviewed for the occurrence of IDRF
(vessel encasement) as described by Monclair et al. [21]. Imaging
showed IDRF-positive tumors in 60% (60 patients) of all analyzed
cases. Correlation analyses with clinical parameters (Suppl. Table 1) re-
vealed a significant association of IDRF-positivity with complications
(p = 0.0023), extent of resection (p = 0.0353), INSS stage (p =
0.0001), encasement (p b 0.0001), UVIN (p b 0,0001) and neoadjuvant
chemotherapy (p b 0.0001). However, OS and EFS showed no statistical
significant difference between IDRF-positive and –negative cases
(Suppl. Fig. 1).
Next, intraoperatively observed in situ encasement of the vessels
was determined and revealed this characteristic in 64% (64 patients)
of all analyzed cases. Correlation analyses of encasement with clinical
parameters showed significant associations with complications (p =
0.0228), extent of resection (p= 0.0182), and neoadjuvant chemother-
apy (p b 0.0001). Strong associations were found with higher grades of
disease, UVIN and IDRF-positivity (each p b 0.0001) (Suppl. Table 2).
2.2. Unexpected vessel infiltration of neuroblastoma (UVIN)
In the course of performing surgical resections on advanced NB pa-
tientswe observed that the degree of vessel encasementwas not always
consistent with the difficulty of tumor removal. Some tumors,
independent of degree of vessel envelopment, adheredmore to the ves-
sel wall than others, thereby impeding surgical resection (Fig. 1). The
presence of this phenomenon cannot be reliably identified in advance
by preoperative imaging.
Evaluation of the documented cases operated on in our department
revealed a frequency of occurrence of unexpected vessel infiltration of
neuroblastoma (UVIN) of 34% (34 patients). 5 tumors (14.7%) showed
a sole infiltration of veins, and 9 tumors (26.5%) a sole infiltration of ar-
teries. In 20 UVIN-positive tumors (58.8%) the infiltration was detected
in both vessel categories. Upon histological staining we found that the
tumor/vessel-interface ofUVIN-positive cases showed tumor cell infiltra-
tionwithin the outer vascular wall layers of large vessels, but without in-
tima and intraluminous involvement (Fig. 2). Immunohistopathological
staining of NSE confirmed the existence of agglomerations of NB cells
in the vessel wall.
2.3. UVIN affects the clinical course of disease
Comparison of clinical characteristics of UVIN-positive and –
negative cases revealed a significant association of UVINwith complica-
tions (p= 0.0344),MYCN amplification (p= 0.0091), the extent of re-
section (p = 0.0045), grade (p = 0.0014), IDRF (p b 0.0001),
encasement (p b 0.0001) and neoadjuvant chemotherapy (p =
0.0002). In a Pearson's chi-square test with metastasis and relapse,
UVIN only showed a significant result with metastasis (p = 0.048).
The other analyzed clinical characteristics showed no statistical signifi-
cance (Table 1). Kaplan–Meier estimates showed a trend towards a sig-
nificant difference of NB with or without UVIN in EFS (p=0.0616) and
Fig. 2. Detailed analysis of vessel infiltrating tumors. a) Schematical graphics (above) demonstrate the essential difference between tumors with vessel encasement (left) and vessel
infiltrating growth (UVIN, right). The vessel itself is not infiltrated in encasing tumors while the UVIN shows an expansion of tumor tissue through outer vessel layers. It is important
to note that the intima remains unaffected. b) This was proven in the histopathological examination. Below a microscopic partial view on a HE – stained (left) and NSE – stained
(right) section of the renal vein, affected by a representative UVIN tumor diagnosed as a Hughes III neuroblastoma; darker agglomerations of NB cells (black arrows) show an
infiltration of the outer vascular walls of vena renalis, but without intraluminous or vessel intima (black star) involvement. Scaling was added for better differentiation of the single
vessel wall layers.
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overall survival (p = 0.0634). Kaplan–Meier estimates with MYCN
stratification showed no significant results in EFS, but significant results
aswell in UVIN positive (p=0.0262) as UVINnegative (p=0.0198) tu-
mors in OS (Fig. 3).
2.4. MYCN and MYCNOS gene expression are unable to predict UVIN
Analysis of MYCN and MYCNOS gene-expression showed a signifi-
cant increase of transcript levels in tumor samples, which were initially
classified asMYCN amplified (p b 0.0001 and p b 0.0006). Furthermore,
we found significant associations of MYCN expression with recurrence
(p = 0.0371) and outcome (p = 0.0112) and MYCNOS expression
with outcome (p = 0.0068) (Table 2). Correlation analysis of MYCN
gene expression level with UVIN did not show a statistically significant
result.
Interestingly, in contrast to MYCN, MYCNOS gene expression levels
showed a significant correlation with UVIN (p=0.0055) (Fig. 4). How-
ever, in 24% of the tumor samples gene expression levels of MYCNOS
were under the detection limit and thus precluded from statistical
analysis.
3. Discussion
Over the last few decades, the appropriate extent of NB surgery has
been an ongoing topic of debate with recommendations from studies
diverging over the need for complete versus incomplete resection
[24]. A recent study suggests improvement of outcome with complete
resection in localized NB. However, for metastatic NB, improvement is
only seen inMYCN amplified tumors and completemacroscopical resec-
tion [25].
One major rationale for incomplete resection is tumor encasement
of the vessels and sometimes even invasive growth into vessel walls
or adjacent organs. However, investigation into this phenomenon,
which we observed in more than a third of our patients, has so far
been limited. Therefore, the purpose of this study was to identify the
clinical and prognostic relevance of this type of invasive tumor growth
form.
IDRF are defined as surgical risk factors. Consistent with recent pub-
lications, IDRF-status in our study population was also significantly as-
sociated with surgical complications, extent of resection and INSS
stage [26]. Furthermore, IDRF diagnosed in pretherapeutic imaging
studies were also significantly associated with intraoperative observa-
tion of vessel encasement and also infiltrative vessel growth. Neverthe-
less, even though elicitation of IDRF status helps with preparation of
surgery, it still is not a reliable factor for prediction of invasive growth.
Despite the fact, that IDRF status was significantly associated with
encasement- and UVIN-status, differentiation between UVIN-positive
and -negative patients and encasement-positive and –negative patients
was not reliably possible using this measure. This may be because pre-
therapeutic imaging, as described by Monclair et al. for compilation of
Fig. 3. Kaplan–Meier analysis of OS (left) and EFS (right) of UVIN without (above) and with MYCN stratification (below). OS (left) was analyzed over 96 months. Tumors with and
without UVIN were compared by log-rank-test at a p-value lower than 0.05. EFS (right) was also analyzed over 96 months. Recurrence or death was defined as events. Tumors with and
without UVINwere compared by log-rank-test at a p-value lower than 0.05. In each analysis a strong trend to a worse outcome in UVIN positive tumors was detectable.WithMYCN strat-
ification (figures below) significant results could be detected as well in UVIN positive as in UVIN negative tumors at the OS analysis. EFS showed no significant results.
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IDRF-status is performed too early (takes place in advanced NB prior to
administration of several cycles of chemotherapy) to allow truly accu-
rate surgical planning and differentiation between these groups. More
likely however it is a result of the limitations of the imaging studies
which are unable to assess the histological degree of tumor invasion
and are therefore an inaccurate tool for prediction of vessel status
[27]. Thus although our results (in a patient cohort that was comparable
to previous studies) further supported the use of the IDRF status in the
planning of surgery in NB patients by demonstrating the strong correla-
tion of an IDRF vessel-positive status with the presence of encasement
and also UVIN, they also highlighted the limitations of this imaging sys-
tem in terms of truly accurate prediction of vessel invasion.
Due to this and the fact, that IDRF, encasement and UVIN all showed
strong correlations with the treatment of neoadjuvant chemotherapy,
we have to assume that there is no proper way for a pre-operative risk
stratification for UVIN so far.
Correlation ofMYCN orMYCNOS gene expression with invasion, mi-
gration and vessel adhesion of tumor cells is also a popular area for cur-
rent research [12,28–30]. Therefore, we analyzed if gene expression
levels correlate with vessel infiltration status.
Our results indicate a relationship between MYCN gene expression
and MYCN amplification, as well as a significant correlation of the gene
expression levels of MYCNOS with the status of MYCN amplification.
These results reflect the previous insights of the obligatory co-
expression and overexpression ofMYCN and MYCNOS and the multiple
described cooperative auto-regulation pathways of the two genes
[14,15,31–33].
However, even though MYCN amplification status was correlated
with vessel infiltrative growth, similar results could not be confirmed
for MYCN gene expression level. Significant correlations with clinical
criteria like recurrence and outcome confirmed once again the impor-
tance ofMYCN amplification as an unfavorable prognosticmarker. How-
ever, the question as to whether MYCN gene expression has the same
importance for the clinical course as MYCN amplification is still not
solved.
Analysis of MYCNOS gene-expression showed a significant correla-
tion with MYCN amplification status, as well as the overexpression of
MYCN gene expression. It also showed a significant correlation between
MYCNOS gene expression and the vessel adhesive growth of NB. How-
ever, the results of our MYCNOS gene expression analysis should be
interpreted with caution because a number of the samples collected
had to be excluded from statistical analysis due to undetectable mRNA
transcript levels (24% of the total samples taken). This could be a poten-
tial source of analytical bias and should be taken into accountwhen con-
sidering the results obtained. It might for example be the cause of our
results showing an apparent correlation betweenMYCNOS gene expres-
sion and vessel adhesive growth in NB even though a correlation be-
tween MYCN gene expression and vessel adhesive growth was not
found. Of note, this was one of the only two areas in which MYCN and
MYCNOS results did not concur in our study.
Alternatively, these results could reflect a real phenomenon such as
the MYCNOS antisense transcript interacting with other molecular fac-
tors that are involved in the vascular adhesion process. This has indeed
been found to be the case in other studies involving NB and bladder can-
cer. In these studies,MYCNOSwas found to act as a co-factor involved in
increasing tumor growth, aggressiveness and vascularization
[12,16,34]. The study by Kaneko et al. provides more information on
the complex interplay between MYCN, MYCNOS and other factors
which induce the transformation of substrate adherent S-cells in NB
[16]. The way in which this, or any other molecular pathways, may be
involved in triggering UVIN is an important area for future research.
Analysis of patients' data demonstrated that UVIN was associated
with a poor clinical course of disease. Although these resultswere statis-
tically not significant, at least a trend towards significance for both EFS
andOSwas seen. Regarding theMYCN stratified analysis, which showed
significant results as well in UVIN positive as in UVIN negative tumors,
one more time the strong impact of MYCN on the course of disease
was shown. Furthermore, the trendof UVINpositive tumors can be visu-
alized in Fig. 3 where the decreased OS und EFS compared to UVIN neg-
ative patients with time is clearly visible.
Of note, with regards to the apparent link between UVIN and a
poorer prognosis are the following factors: Firstly, the overall number
of study participants was low thus making the demonstration of statis-
tical significance more difficult to achieve. Secondly, patient treatment
wasnot uniform across the cohort and thus external factors (eg. number
of chemotherapy cycles received and their potential effect on the inva-
siveness of NB) may be playing a confounding role in the results ob-
tained. Thirdly, it is not clear whether the UVIN is the cause of the
poorer prognosis or whether it is merely an indicator of another, as
yet unknown, underlying molecular factor that is actually responsible
for driving the progression of the disease.
4. Conclusion
Our study demonstrates the value of further risk stratification in the
assessment of NB, above and beyond the existing IDRF status method.
We propose that NB tumors should also be classified according to the
degree of in situ vessel encasement and according to the presence or ab-
sence of UVIN. Given that these factors represent not only a major sur-
gical problem, but also affect the clinical course of the disease, we
suggest the regular identification of the UVIN and encasement status
Fig. 4. MYCNOS gene expression in UVIN-positive and -negative NB. MYCNOS gene
expression levels were quantified by real time PCR relative to TBP (TATA – box –
binding protein) housekeeping gene. Statistical analysis of MYCNOS gene expression
levels with GraphPad Prism showed a significant difference between UVIN-positive
and –negative NB in Mann–Whitney test at a p-value lower than 0.05.
Table 2
Correlation of MYCN/MYCNOS gene expression rates with clinical characteristics and
UVIN Gene expression levels were analyzed with real time qPCR and normalized to TBP
housekeeping gene expression. Correlation with given parameters was analyzed with
GraphPad PrismMann–Whitney test at a p-value lower than 0.05. Significant results (bold
printed) were found in MYCN with recurrence, MYCN-amplification status and outcome,






MYCN – amplification b0.0001 b0.0006
Sex 0.9658 0.5653
Grade 0.4396 0.1706
Extent of resection 0.9391 0.644
Age at first diagnosis 0.7852 0.231
Outcome 0.0112 0.0068
Significant results are now marked as bold-printed.
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in every NB by the operating surgeon. Also if the definitionmay depend
on the surgeon's experience, a postoperative characterization – combin-
ing the surgeon's evaluation and the histopathological analysis –would
be desirable to collect data for further studies on this phenomenon. This
additional classification process has prognostic implications and may
therefore allow the application of more tumor-specific therapeutic
management programs in the future. Unfortunately our results do not
support a role for gene expression levels of MYCN and MYCNOS as a
marker for UVIN at this present time. Further larger prospective studies
are needed to understand the cause and implications of UVIN and the
role thatMYCN andMYCNOS or other genes, which have yet to be iden-
tified, play in this process.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jpedsurg.2019.07.012.
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Abstract. Background: Neuroblastoma is an embryonal
malignancy arising from the aberrant growth of neural
crest progenitor cells of the sympathetic nervous system.
The tachykinin receptor 1 (TACR1) – substance P complex
is associated with tumoral angiogenesis and cell
proliferation in a variety of cancer types. Inhibition of
TACR1 was recently described to impede growth of NB cell
lines. However, the relevance of TACR1 in clinical settings
is unknown. Patients and Methods: We investigated gene
expression levels of full-length and truncated TACR1 in 59
neuroblastomas and correlated these data with the
patients’ clinical parameters such as outcome, metastasis,
International Neuroblastoma Staging System (INSS) status,
MYCN proto-oncogene, bHLH transcription factor
(MYCN) status, gender and age. Results: Our results
indicated that TACR1 is ubiquitously expressed in
neuroblastoma but expression levels are independent of
clinical parameters. Conclusion: Our data suggest that
TACR1 might serve as a potent anticancer target in a large
variety of patients with neuroblastoma, independent of
tumor biology and clinical stage. 
Neuroblastoma (NB), an embryonal malignancy arising from
the aberrant growth of neural crest progenitor cells of the
sympathetic nervous system, is the most common solid
extracranial tumor found in infancy and childhood (1-3). NB
is characterized by its clinical heterogeneity: whereas very
young children often demonstrate spontaneous tumor
regression, older children frequently suffer from progressive
disease with poor outcome. Although recent therapeutic
approaches in multimodal therapies demonstrated better
overall survival, more than 50% of children with high-risk
disease do not respond to modern chemotherapy regimens,
resulting in progressive disease. Overall, NB accounts for
12% of all pediatric oncological deaths (1, 3-6). 
On the molecular level, several mutations have been
discovered for NB. For this and other reasons, NB has served
as a paradigm for biological risk assessment and treatment
assignment. For example, amplification of MYCN proto-
oncogene, bHLH transcription factor (MYCN) and
hemizygous deletion of chromosomes 1p and 11q are found
in up to 30% of patients with NB and are known to correlate
with worse outcome and poor prognosis(2). However, the
exact mechanisms of tumor formation and progression are
still incompletely understood and other oncogenic drivers of
tumorigenesis are still to be discovered (2).
Substance P (SP)–tachykinin receptor 1 (TACR1) (also
named neurokinin-1 receptor) complex, which acts as a
neuronal transmitter, has been linked to inflammation and
cell migration (7). Furthermore, several studies have reported
that activation of TACR1 (through binding of SP) is
associated with tumoral angiogenesis and cell proliferation
(8). Among the three subtypes of tachykinin receptors,
TACR1 has the highest affinity for the ligand SP (9). 
Two splice variants of TACR1 are known: a full-length
variant (fl-TACR1) and a truncated variant (tr-TACR1). The
latter lacks 100 amino acids at its C-terminal end, which
serves as a substrate for G protein receptor kinases and has
been reported to differ in its biological function in interaction
with SP (10). As a consequence of splicing, the truncated
variant lacks sensitivity for negative feedback inhibition,
leading to constant activation of the receptor complex(11).
Several studies revealed the importance of tr-TACR1 in
cancer (10-13).
Importantly, the SP–TACR1 receptor system was recently
described to be a potent anticancer target in NB (14). In the
present study, we investigated the role and clinical relevance
of fl-TACR1 and tr-TACR1 in tumor samples from children
with NB. 
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Patients and Methods
Patients and tumor tissues. Between 2009 and 2014, 59 patients
with NB underwent either biopsy or surgical resection in our
Department. Patients were all treated according to the protocol of
the German Society of Pediatric Oncology and Hematology (GPOH,
study protocol NB2004). For this study, the patients’ charts were
reviewed retrospectively regarding clinical information: age, gender,
International Neuroblastoma Staging System (INSS) status,
outcome, metastasis, MYCN status, histology, and extent of surgical
resection were obtained and correlated with gene-expression data. 
Extent of surgical resection was noted as biopsy only when less
than 50% of the tumor mass was removed. An incomplete resection
was defined as when more than 50% but less than 89% of the tumor
was macroscopically removed. Resection of more than 90% of
tumor but still with visible tumor remnants (90-99%) was
considered a near-complete resection. Removal of 100%
macroscopical tumor mass was considered complete resection (15). 
This study was approved by the Institutional Ethics Committee
of the University Hospital (LMU Munich; N. 431-11). Written
consent was given by the patients’ parents for collection of data and
laboratory analysis. 
RNA extraction and reverse transcription. In essence, samples were
treated with TRIzol® reagent for isolation of RNA, according to the
manufacturer’s instructions (Invitrogen Life Technologies, Carlsbad,
CA, USA). RNA was dissolved in RNase-free water. Reverse
transcription of RNA-samples (2 μg each) was performed utilizing
SuperScriptTM II reverse transcriptase (Invitrogen Life
Technologies), as recommended by the supplier. 
Reverse transcription polymerase chain reaction (RT-PCR). Two
microliters of cDNA sample were utilized in each PCR reaction with
the following specific primers for fl-TACR1 and tr-TACR1 as well as
TATA-box-binding-protein (TBP) housekeeping gene: For fl-TACR1:
Forward, 5’-AACCCCATCATCTACTGCTGC-3’ and reverse, 5’-
ATTTCCAGCCCCTCATAGTCG-3’ (NM_001058.3); for tr-TACR1
forward, 5’-GGGCCACAAGACCATCTACA-3’ and reverse, 5’-
AAGTTAGCTGCAGTCCCCAC-3’ (NM_015727.2); and for TBP:
forward, 5’-GCCCGAAACGCCGAATAT-3’ and reverse, 5’-
CCGTGGTTCGTGGCTCTCT-3’. Samples for amplification
reactions had a final volume of 20 μl. iTaq SYBR-green Supermix
(Bio-Rad Laboratories, Hercules, CA, USA) was used for
amplification reactions. Samples were incubated at 95˚C for 7 min,
followed by 40 cycles of 95˚C for 30 s, 60˚C for 30 s and 72˚C for
30 s, with the final extension cycle performed at 72˚C for 7 min. The
transcript numbers were normalized according to the expression of
the housekeeping gene. Relative quantification of gene expression
was performed using the 2 -ΔΔCt method as described by Pfaffl (16).
Statistical analysis. Results are given as the mean±standard error of
the mean. Gene-expression levels of tumor samples are displayed
as dot plots for each group. Correlation analysis was performed
using a Mann–Whitney U-test and a standard t-test. Differences
with a p-value of less than 0.05 were considered as statistically
significant. Statistical calculations were performed using biostatics
software from GraphPAD Prism® (La Jolla, CA, USA).
Kaplan–Meier curves were used for demonstration of overall
survival (OS), and two-sided log-rank test was utilized for
comparison of survival curves. 
Results
TACR1 shows high expression in human NB. Gene-
expression profiles of fl-TACR1 and tr-TACR1 were
investigated in human NB samples. In general, fl-TACR1
showed a low expression profile, whereas tr-TACR1
demonstrated much higher expression levels in NB samples
(Figure 1a). This difference was statistically significant
(p<0.0001). However, fl-TACR1 and tr-TACR1 expression
did not demonstrate a significant correlation (r=0.2201,
p=0.0969) (Figure1b). Furthermore, we performed an
analysis of the association between expression of each splice
variant (with cutoff as the overall mean expression) and
overall prognosis. There was no statistically significant
difference for either splice variant (Figure 1c). 
Clinical characteristics. The mean patient age at diagnosis
was 40.5 months, with a range from 0 months to 19.2 years.
Twenty-six patients (44.1%) had metastases at diagnosis. For
further patient characteristics, see Table I.
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Table I. Patient characteristics.
                                                                                 Patients (n)          %
Gender                                                                                                     
    Female                                                                        26                 44.1
    Male                                                                           33                 55.9
Histology                                                                                                 
    Ganglioneuroma (GN)                                                 5                   8.5
    Ganglioneuroblastoma (G1)                                      19                 32.2
    Differentiated neuroblastoma (G2)                           14                 23.7
    Undifferentiated neuroblastoma (G3)                       21                 35.6
Outcome                                                                                                  
    Alive                                                                           46                 77.9
    Died from disease                                                      13                 22.1
Extent of surgery                                                                                    
    Biopsy only                                                                  2                   3.4
    Incomplete resection (<50%-90%)                             6                 10.2
    Nearly complete resection (>90-99%)                      24                 40.7
    Complete resection (100%)                                       27                 45.7
MYCN status                                                                                           
    Amplified                                                                      6                 10.2
    Not amplified                                                             53                 89.8
Metastasis                                                                                                
    Yes                                                                              26                 44.1
    No                                                                               33                 55.9
International Neuroblastoma Staging System                                       
    1                                                                                    6                 10.2
    2a                                                                                   6                 10.2
    2b                                                                                  1                   1.7
    3                                                                                  20                 33.9
    4                                                                                  25                 42.3
    4s                                                                                   1                   1.7
MYCN: MYCN proto-oncogene, bHLH transcription factor.
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Gene-expression levels of fl-TACR1 and tr-TACR1. Both fl-
TACR1 and tr-TACR1 variants as well as their ratio were
analyzed for association with clinical and biological findings
of NB samples. Neither fl-TACR1 nor tr-TACR1 were
significantly associated with histology, age or gender (Figure
2). Clinical parameters such as MYCN status and metastasis,
which are linked with aggressive disease, also demonstrated
no significant association with tr-TACR1 nor fl-TACR1. Only
fl-TACR1 was significantly higher in INSS stage 4 (p=0.0164,
Figure 3), but there was no association for tr-TACR1 nor their
ratio. As was the case for the other clinical parameters
mentioned, the analysis of gene-expression levels did not
show any significant association with outcome (Figure 3).
Discussion
An abundance of studies have proven the importance of the
SP–TACR1 complex in cancer and disease progression (7,
10). Moreover, during the past decade, TACR1 and its high
expression in a variety of cancer types has become the focus
of attention for targeted therapy. Tachykinin-receptor
antagonists such as aprepitant, currently used as a clinical
drug for the treatment of chemotherapy-related nausea and
vomiting, in several reports demonstrated in vitro and in vivo
efficacy against TACR1, resulting in a robust anticancer
effect (12, 14, 17). Similar effects have been observed for
other TACR1 antagonists. 
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Figure 1. a: Gene-expression of full-length tachykinin receptor 1 (fl)-TACR1 and truncated (tr)-TACR1 in human neuroblastoma samples. b:
Correlation between fl-TACR1 and tr-TACR1. c: Association between expression of each splice variant (with cut-off as the overall mean expression)
and overall prognosis.
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Little is known about the role of TACR1 in oncogenesis
and tumor progression in NB. Nowicki et al. investigated the
cell immunophenotype of metastatic and primary tumors in
NB and found, among other nervous tissue markers, high
expression of SP in both groups (18). In 2005, Munoz et al.
reported TACR1 expression in two NB cell lines (19).
Perhaps the most sophisticated study regarding this topic so
far was recently published by Henssen et al. The authors
examined tachykinin receptors in a panel of NB cell lines.
Their results suggest TACR1 expression in all tested cell
lines, even though expression levels varied. Our previous
studies in hepatoblastoma are consistent with this finding
(12, 14). In a second step, growth inhibition was induced
with targeting NB cells in vivo and in vitro (mouse xenograft
model) with fosaprepitant, a tachykinin receptor antagonist
similar to aprepitant. The Authors concluded that gene
expression of TACR1 is increased in NB cell lines resulting
in expression of this receptor, making it an attractive target
for targeted therapy with TACR1 antagonists (14).
Interestingly, NB is currently the only solid cancer in
ANTICANCER RESEARCH 37: 6079-6085 (2017)
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Figure 2. Gene-expression of full-length tachykinin receptor 1 (fl)-TACR1 and truncated (tr)-TACR1, and their ratio in human neuroblastoma samples
according to histology, age and gender. GN: Ganglioneuroma, G1: gangioneuroblastoma, G2: differentiated neuroblastoma, G3: undifferentiated
neuroblastoma, yr: year, F: female, M: male.
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Figure 3. Gene-expression of full-length tachykinin receptor 1 (fl)-TACR1 and truncated (tr)-TACR1, and their ratio in human neuroblastoma samples
according to MYCN proto-oncogene, bHLH transcription factor (MYCN) status, presence of metastasis, International Neuroblastoma Staging System
(INSS), and outcome. DOD: Died of disease. 
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childhood for which a positive therapeutic effect has been
proven for targeted therapy (via GD2). This understanding
raises hope that there could potentially be other targets via
which a similarly promising effect can be achieved.
In the present study, we demonstrated ubiquitous gene
expression of fl-TACR1 and tr-TACR1 in a cohort of children
with NB. Our results suggest increased gene expression of tr-
TACR1 and low expression of fl-TACR1 in NB tumor tissue.
Interestingly, gene expression levels were independent of
clinical markers such as INSS stage, MYCN status and
histology. These findings are in accordance with what has
been found for other tumor types. As was briefly mentioned
above, it is generally understood that it is the expression of
the truncated splice variant that is dominantly involved in
cancer formation (20, 21). This finding strongly correlates
with our own data published recently for the expression profile
of the SP–TACR1 receptor system in hepatoblastoma, another
aggressive childhood cancer (11, 12). Compared to normal
liver tissue, we found that gene expression levels of fl-TACR1
and tr-TACR1 were both increased, whereas the level of tr-
TACR1 was significantly increased compared to fl-TACR1
(p=0.0301) (11). Similar to the results presented here for NB,
in hepatoblastoma, we found no correlation between the
expression profile of TACR1 and clinical behavior or disease
stage. Yet TACR1 antagonists had a  remarkable therapeutic
effect on hepatoblastoma growth both in vitro and in vivo. 
Our findings presented in this study are furthermore in
accordance with those of other studies. Chen et al. examined
expression of SP and TACR1 in tissue microarrays of
colorectal cancer and adjacent healthy tissue with
immunohistochemistry. Expression of SP and TACR1 were
both significantly increased in samples of patients with
lymph node metastasis; furthermore, high TACR1 expression
was also correlated with TNM stage III and IV. Besides these
significant correlations, expression of SP and TACR1 was not
associated with clinical parameters such as age, sex, gender,
distant metastasis and pathological grading (7). 
Somewhat different results were found in a recent study in
breast cancer (10). The different role of fl- and tr-TACR1 in
breast cancer cell lines and breast cancer tumor samples were
investigated. The authors found high gene-expression levels
of tr-TACR1 in cells of advanced malignancy, whereas fl-
TACR1 demonstrated mainly high gene-expression levels in
normal breast and mesenchymal cells; in breast cancer cells,
gene expression of fl-TACR1 was markedly reduced (10).
Moreover, results suggest that fl-TACR1 was inversely
correlated with invasiveness, proliferation and metastasis,
whereas high expression of tr-TACR1 seemed to affect
progressive disease and metastasis. Interestingly, we found
similar results when investigating hepatoblastoma (12),
however, as mentioned above, we did not find any correlation
between disease stage or prognosis for the data presented here
in NB nor for hepatoblastoma presented previously. 
As all scientific studies, ours has several flaws, potentially
biasing our data. Firstly, we only investigated gene-expression
levels not protein-expression levels. Just as there are variations
in the splice products prior to expression, there could be
mRNA abrogation or other mechanisms that alter the
expression profile that we did not account for. The solution to
this would be immunohistochemical staining of our samples
in order to correlate the protein-expression profile with the
mRNA profile. Although such staining is generally feasible, it
is increasingly challenging given the unavailability of
appropriate antibodies against the tr-TACR1 (20). Thirdly, NB
is a very heterogeneous tumor. By taking one sample per
tumor, the examined areas might not be representative of the
whole specimen. Furthermore, we lacked a control group with
healthy tissue to compare gene-expression levels simply due
to the nature of the tumor type we investigated. 
Nevertheless, despite these limitations, we feel that our
findings support evidence that NB tissue, similarly to other
cancer types, ubiquitously expresses TACR1. This
understanding could hold tremendous clinical relevance and
make TACR1 an attractive therapeutic target for a large
variety of clinical and biological NB subsets. Further
research is needed to clarify the exact clinical and biological
role of TACR1 in the oncogenesis of childhood NB. 
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